Marksans Pharma has announced that its wholly owned UK subsidiary, Relonchem, has received Marketing Authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its Exemestane 25 mg film-coated tablets.

Exemestane is an aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. The approval marks another milestone in Marksans Pharma’s strategy to expand its oncology portfolio and strengthen its presence in the UK and European markets.

Marksans Pharma, listed on NSE (MARKSANS) and BSE (524404), continues to enhance its global footprint through strategic product launches and regulatory approvals across key therapeutic segments.